Tranexamic Acid and Pigmentation
The primary action of tranexamic acid lies in its ability to inhibit plasminogen activation, thereby preventing the conversion of plasminogen to plasmin. In the context of melasma, this is significant because ultraviolet (UV) radiation induces keratinocytes to release plasmin, which then increases the production of arachidonic acid and prostaglandins—substances that stimulate melanogenesis. By reducing plasmin activity, TXA indirectly inhibits the cascade leading to increased melanin production. Additionally, TXA may reduce vascular endothelial growth factor (VEGF) expression, which contributes to the vascular component often seen in melasma lesions.
Topical Serums and the Stratum Corneum Barrier
Topical formulations of tranexamic acid have become increasingly popular due to their safety profile and ease of use. However, one of the major limitations of topical TXA is the stratum corneum, the outermost layer of the skin. This barrier is highly effective at preventing the penetration of hydrophilic and large-molecule substances like tranexamic acid, thus limiting its ability to reach the deeper layers of the epidermis and the dermal-epidermal junction (DEJ), where melanogenesis is actively regulated.
Next-Generation Serums and Targeted Delivery
Recent advancements in dermatologic formulation have aimed to overcome the stratum corneum barrier to deliver active agents more effectively to their target sites. New-generation tranexamic acid serums claim to use technologies such as liposomal encapsulation, microneedle patches, or nanoemulsions to enhance skin penetration. These carriers are designed to bypass or transiently disrupt the stratum corneum, delivering TXA closer to the DEJ where melanocytes reside.
One promising example includes liposomal TXA, in which the acid is encapsulated in lipid-based vesicles that merge with the skin’s lipid matrix, enhancing percutaneous absorption. Some clinical data suggest improved efficacy with these novel formulations, though large-scale, peer-reviewed trials are still limited.
Tranexamic acid represents a versatile and increasingly well-regarded option in the treatment of melasma, offering both oral and topical applications. While oral TXA provides deeper systemic action, it carries greater risk, making topical treatments attractive for long-term management. As delivery technologies improve, the potential for topical TXA to reach and act upon the DEJ may finally bridge the gap between safety and efficacy in melasma treatment
